|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0086 USD | 0.00% |
|
0.00% | -95.41% |
| 05/03 | Akari Therapeutics, Plc entered into a definitive agreement to acquire Peak Bio, Inc.. | CI |
| 16/02 | Peak Bio, Inc. announced that it has received $2.238 million in funding | CI |
Peak Bio, Inc. filed its 10-K on Jun 29, 2023 for the period ending Dec 31, 2022. In this report its auditor, Mayer Hoffman McCann P.C., gave an unqualified opinion expressing doubt that the company can continue as a going concern.
| 1st Jan change | Capi. | |
|---|---|---|
| -95.41% | 199K | |
| +50.40% | 56.69B | |
| -2.93% | 41B | |
| +38.14% | 38.11B | |
| -11.22% | 26.89B | |
| +15.22% | 25.59B | |
| -22.54% | 18.59B | |
| +0.16% | 12.39B | |
| +26.90% | 11.99B | |
| +22.86% | 11.88B |
PEAK BIO, INC. 
